April 13th 2021, 9:00pm
Several factors were associated with patients undergoing radical nephrectomy compared with radical nephroureterectomy including Black race, large tumors, advanced tumor stage and high-grade tumors.
April 13th 2021, 7:37pm
Trodelvy has received accelerated approval from the FDA for the treatment of patients with advanced urothelial cancer.
April 12th 2021, 9:00pm
Adjusting the dose of cisplatin, when added to regular doses of Abraxane and gemcitabine, led to similar survival rates when treating patients with advanced/metastatic urothelial carcinoma, which may help to address issues commonly seen with patients who cannot tolerate cisplatin such as renal dysfunction.
March 9th 2021, 2:00pm
If patients were receiving Tecentriq for prior platinum-based treated metastatic urothelial carcinoma, they should discuss next best steps with their health care providers.
March 4th 2021, 10:00pm
While it is important to educate oneself after receiving a diagnosis of cancer, it’s also critical to know when to step away and find a balance between cancer and life, according to Diane Zipursky-Quale.
February 24th 2021, 10:00pm
To discuss the projected rise in bladder cancer cases in 2021, CURE® spoke with Bladder Cancer Advocacy Network (BCAN) co-founder Diane Zipursky-Quale, who offered some insight on why the numbers continue to rise, and provides some hope in the form of educational programs offered by her organization.
February 15th 2021, 10:00pm
Treatment with Padcev, compared to chemotherapy, continues to show better results in patients with advanced urothelial carcinoma who had previously received certain therapies.
February 15th 2021, 1:00pm
In Episode 2 of the “Bladder Cancer Matters” podcast, host Rick Bangs interviews Dr. Heather Honoré Goltz in Part 2 of a two-part episode.
February 14th 2021, 12:30pm
The Bladder Cancer Advocacy Network's new podcast by, for, and about the bladder cancer community, "Bladder Cancer Matters," has a new episode available.
February 2nd 2021, 2:34pm
In the inaugural “Bladder Cancer Matters” podcast, host Rick Bangs interviews Dr. Ashish Kamat about the state of BCG in bladder cancer treatment. Dr. Kamat is a Professor (Tenure) of Urology and Director of Urologic Oncology Fellowship at MD Anderson Cancer Center, and a graduate of the AUA Leadership Program. Dr. Kamat also serves on BCAN’s Scientific Advisory Board.
Ayvakit Shows Promise for Patients with Gastrointestinal Stomach Tumors With Specific Mutation
Survivorship Champions
FDA Approves Opdivo for the Frontline Treatment of Gastric Cancer
Learning to be a Kinder Person After Cancer
